Linxiang Lan - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Linxiang Lan

Showing results (21-30 of 24) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 24 results.

Cancer Immunology, Immunotherapy : CII|July 3, 2026

NKG2A-HLA-E and TIM3-galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancreatic ductal adenocarcinomaYuanyu Lin, Wanhua Feng, Yan Li, et al.

Nature|September 24, 2025

SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancerHuafu Li, Linxiang Lan, Hengxing Chen, et al.

Nature|June 29, 2022

GREM1 is required to maintain cellular heterogeneity in pancreatic cancerLinxiang Lan, Theodore Evan, Huafu Li, et al.

Elife|October 12, 2021

USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinomaE Josue Ruiz, Adan Pinto-Fernandez, Andrew P Turnbull, et al.

Pageof 3

Search research articles

Showing results (21-30 of 24) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 24 results.

Cancer Immunology, Immunotherapy : CII|July 3, 2026

NKG2A-HLA-E and TIM3-galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancreatic ductal adenocarcinomaYuanyu Lin, Wanhua Feng, Yan Li, et al.

Nature|September 24, 2025

SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancerHuafu Li, Linxiang Lan, Hengxing Chen, et al.

Nature|June 29, 2022

GREM1 is required to maintain cellular heterogeneity in pancreatic cancerLinxiang Lan, Theodore Evan, Huafu Li, et al.

Elife|October 12, 2021

USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinomaE Josue Ruiz, Adan Pinto-Fernandez, Andrew P Turnbull, et al.

Pageof 3